Grasselly C, Denis M, Bourguignon A, Talhi N, Mathé D, Tourette A, et al. The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. Front Immunol. 2018;9:2100 pubmed publisher

Stathopoulou C, Gangaplara A, Mallett G, Flomerfelt F, Liniany L, Knight D, et al. PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells. Immunity. 2018;49:247-263.e7 pubmed publisher

Kim J, Jeong Ryu S, Oh K, Ju J, Yeong Jeon J, Nam G, et al. Memory programming in CD8(+) T-cell differentiation is intrinsic and is not determined by CD4 help. Nat Commun. 2015;6:7994 pubmed publisher

Ngiow S, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, et al. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res. 2015;75:3800-11 pubmed publisher

Tkachev V, Goodell S, Opipari A, Hao L, Franchi L, Glick G, et al. Programmed death-1 controls T cell survival by regulating oxidative metabolism. J Immunol. 2015;194:5789-800 pubmed publisher

Zander R, Obeng Adjei N, Guthmiller J, Kulu D, Li J, Ongoiba A, et al. PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity. Cell Host Microbe. 2015;17:628-41 pubmed publisher

Twyman Saint Victor C, Rech A, Maity A, Rengan R, Pauken K, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373-7 pubmed publisher

Jaworska K, Ratajczak J, Huang L, Whalen K, Yang M, Stevens B, et al. Both PD-1 ligands protect the kidney from ischemia reperfusion injury. J Immunol. 2015;194:325-33 pubmed publisher

Dolina J, Braciale T, Hahn Y. Liver-primed CD8+ T cells suppress antiviral adaptive immunity through galectin-9-independent T-cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice. Hepatology. 2014;59:1351-65 pubmed publisher

Yang X, Zhang X, Fu M, Weichselbaum R, Gajewski T, Guo Y, et al. Targeting the tumor microenvironment with interferon-? bridges innate and adaptive immune responses. Cancer Cell. 2014;25:37-48 pubmed publisher

Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum R, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687-95 pubmed publisher

Dietze K, Zelinskyy G, Liu J, Kretzmer F, Schimmer S, Dittmer U. Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific CD8+ T cells and efficiently reduces chronic retroviral loads. PLoS Pathog. 2013;9:e1003798 pubmed publisher

Rutigliano J, Sharma S, Morris M, Oguin T, McClaren J, Doherty P, et al. Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells. J Virol. 2014;88:1636-51 pubmed publisher

Willimsky G, Schmidt K, Loddenkemper C, Gellermann J, Blankenstein T. Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. J Clin Invest. 2013;123:1032-43 pubmed publisher

Hafalla J, Claser C, Couper K, Grau G, Renia L, de Souza J, et al. The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology. PLoS Pathog. 2012;8:e1002504 pubmed publisher

Riella L, Watanabe T, Sage P, Yang J, Yeung M, Azzi J, et al. Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts. Am J Transplant. 2011;11:832-40 pubmed publisher

Zhang L, Gajewski T, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009;114:1545-52 pubmed publisher